NAMS Menopause Certification Exam
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: A 52-year-old woman presents with 8 hot flashes per day, night sweats 3–4 times weekly,
vaginal dryness, and irregular menses occurring every 30–90 days. Her last menstrual period was 7
months ago. Her FSH is 38 mIU/mL, estradiol is 42 pg/mL, and TSH is 2.1 mIU/L. She has no
personal history of breast cancer, no VTE, and an intact uterus. According to STRAW+10 criteria,
what is her reproductive aging stage?
A. Early menopausal transition (stage -2)
B. Late menopausal transition (stage -1) [CORRECT]
C. Early postmenopause (stage +1a)
D. Late postmenopause (stage +2)
Correct Answer: B
Rationale: Correct because STRAW+10 defines late menopausal transition (stage -1) as the interval
from the first occurrence of ≥60 days of amenorrhea through 12 months after the final menstrual
period (FMP). This patient's last period was 7 months ago with FSH >35 mIU/mL and low estradiol,
placing her in stage -1. The ≥60-day amenorrhea criterion has been met, distinguishing this from
early transition (stage -2), which requires cycle length variation of ≥7 days.
Q2: A 48-year-old woman with a history of breast cancer treated with lumpectomy and radiation 5
years ago, currently on tamoxifen, presents with severe vasomotor symptoms affecting her quality of
life. She asks about hormone therapy. According to NAMS guidelines, what is the most appropriate
response?
A. Transdermal estradiol with micronized progesterone is safe in her case
B. Systemic estrogen-progestogen therapy is contraindicated due to her breast cancer history
[CORRECT]
C. Vaginal estrogen alone is contraindicated
D. Oral conjugated equine estrogen alone is acceptable given her tamoxifen use
Correct Answer: B
Rationale: Correct because a history of estrogen-dependent breast cancer is an absolute
contraindication to systemic menopausal hormone therapy per NAMS 2026 position statement.
While low-dose vaginal estrogen may be considered in select cases after discussion with oncology,
systemic estrogen-progestogen therapy is contraindicated. Tamoxifen does not mitigate the risk of
estrogen exposure in breast cancer survivors.
,Q3: Which of the following hormonal changes is the EARLIEST biomarker of declining ovarian
reserve during the menopause transition?
A. Rising FSH
B. Declining estradiol
C. Declining anti-Müllerian hormone (AMH) [CORRECT]
D. Rising LH
Correct Answer: C
Rationale: Correct because AMH is produced by granulosa cells of preantral and small antral
follicles and declines first in the reproductive aging process, often 5–10 years before FSH rises.
AMH is the earliest detectable hormonal marker of ovarian aging, making it the most sensitive
biomarker of declining ovarian reserve. FSH and LH rise later as negative feedback from estradiol
and inhibin B wanes.
Q4: A 60-year-old postmenopausal woman with osteoporosis (T-score -2.8 at the lumbar spine) and
moderate vasomotor symptoms cannot take MHT due to a history of VTE. Which non-hormonal
pharmacologic option has the strongest evidence for VMS reduction?
A. Black cohosh
B. Gabapentin
C. Paroxetine (7.5 mg) [CORRECT]
D. Acupuncture
Correct Answer: C
Rationale: Correct because paroxetine mesylate 7.5 mg (Brisdelle) is the only non-hormonal agent
FDA-approved for moderate-to-severe VMS and has the strongest evidence base among non-
hormonal options per NAMS guidelines. Gabapentin and venlafaxine have moderate evidence, while
black cohosh and acupuncture have inconsistent or limited evidence for VMS relief.
Q5: According to the timing hypothesis ("age and time" rule) for MHT initiation, what is the
maximum time from menopause onset for women under age 60 to initiate therapy and likely benefit?
A. 5 years
B. 8 years
C. 10 years [CORRECT]
D. 15 years
Correct Answer: C
Rationale: Correct because the timing hypothesis, supported by WHI reanalysis and NAMS 2026
guidelines, states that initiation of MHT within 10 years of menopause onset or before age 60 is
associated with more favorable benefit-risk ratios, particularly for cardiovascular outcomes. Beyond
this window, risks may outweigh benefits, especially for women initiating therapy after age 60.
,Q6: A 55-year-old woman with an intact uterus is started on MHT. She is prescribed transdermal
estradiol 0.05 mg/day. Which progestogen is most appropriate for endometrial protection according
to NAMS guidelines?
A. Medroxyprogesterone acetate (MPA) 10 mg daily
B. Norethindrone acetate 5 mg daily
C. Micronized progesterone 200 mg daily for 12 days per cycle [CORRECT]
D. Drospirenone 3 mg daily
Correct Answer: C
Rationale: Correct because NAMS 2026 guidelines recommend micronized progesterone or
dydrogesterone as the preferred progestogens for endometrial protection when combined with
estrogen in women with an intact uterus, due to a more favorable safety profile compared to
synthetic progestins like MPA. Micronized progesterone has lower breast cancer risk and does not
negate the cardiovascular benefits of transdermal estrogen.
Q7: What is the definition of premature ovarian insufficiency (POI)?
A. Menopause before age 45
B. Menopause before age 50
C. Menopause before age 40 [CORRECT]
D. Amenorrhea for 6 months before age 40
Correct Answer: C
Rationale: Correct because POI is defined as the loss of ovarian function before age 40,
characterized by amenorrhea (or oligomenorrhea) for ≥4 months with elevated FSH (>25 mIU/mL
on two occasions >4 weeks apart). Early menopause is defined as FMP before age 45, and late
menopause as FMP after age 54. POI requires confirmation with elevated gonadotropins.
Q8: A 58-year-old woman presents for her annual wellness visit. She has a DEXA T-score of -2.1 at
the femoral neck and -1.8 at the lumbar spine. She has no fractures but has a 10-year FRAX
probability of major osteoporotic fracture of 18%. According to NAMS and NOF guidelines, what is
the most appropriate initial pharmacologic management?
A. Calcium and vitamin D alone with repeat DEXA in 2 years
B. Oral bisphosphonate (alendronate or risedronate) [CORRECT]
C. Teriparatide as first-line therapy
D. Raloxifene
Correct Answer: B
Rationale: Correct because for a postmenopausal woman with osteopenia (T-score between -1.0 and
-2.5) and a 10-year FRAX major osteoporotic fracture risk ≥20% (or hip fracture risk ≥3%),
pharmacologic therapy is indicated. Oral bisphosphonates (alendronate, risedronate) are first -line per
NAMS and NOF guidelines. Teriparatide is reserved for high-risk patients or those who fail/cannot
tolerate bisphosphonates.
, Q9: Which ethnic/racial group of women has been shown to have lower estradiol levels during the
menopause transition compared to White, Black, and Hispanic women?
A. South Asian women
B. Chinese and Japanese women [CORRECT]
C. Native American women
D. Middle Eastern women
Correct Answer: B
Rationale: Correct because the Study of Women's Health Across the Nation (SWAN) and other
epidemiologic data have demonstrated that Chinese and Japanese women have lower estradiol levels
during the menopause transition compared to White, Black, and Hispanic women. This finding has
implications for symptom severity and MHT dosing in these populations.
Q10: A 50-year-old woman with an intact uterus is on oral conjugated equine estrogen (CEE) 0.625
mg daily for VMS. She develops new-onset leg swelling and is found to have a proximal DVT.
According to NAMS guidelines, which route of estrogen would have carried the LOWEST VTE
risk?
A. Oral estradiol
B. Oral CEE
C. Transdermal estradiol (patch or gel) [CORRECT]
D. Vaginal estradiol tablet
Correct Answer: C
Rationale: Correct because transdermal estrogen bypasses first-pass hepatic metabolism and does
not increase hepatic synthesis of clotting factors, resulting in a significantly lower risk of VTE
compared to oral estrogen. NAMS 2026 guidelines specifically recommend transdermal over oral
estrogen for women with VTE risk factors. Oral estrogen increases VTE risk 2- to 4-fold, while
transdermal estrogen shows no significant increase.
Q11: A 48-year-old woman with POI due to autoimmune oophoritis is currently on MHT. According
to NAMS guidelines, MHT should be continued until at least what age?
A. Age 50
B. Age 51 (mean age of natural menopause) [CORRECT]
C. Age 55
D. Age 60
Correct Answer: B
Rationale: Correct because NAMS guidelines recommend that women with POI should receive
MHT at least until the average age of natural menopause (approximately age 51) to protect bone,
cardiovascular, and neurological health, as their estrogen deficiency is premature and not age-
appropriate. MHT may be continued beyond age 51 based on individual risk-benefit assessment.
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: A 52-year-old woman presents with 8 hot flashes per day, night sweats 3–4 times weekly,
vaginal dryness, and irregular menses occurring every 30–90 days. Her last menstrual period was 7
months ago. Her FSH is 38 mIU/mL, estradiol is 42 pg/mL, and TSH is 2.1 mIU/L. She has no
personal history of breast cancer, no VTE, and an intact uterus. According to STRAW+10 criteria,
what is her reproductive aging stage?
A. Early menopausal transition (stage -2)
B. Late menopausal transition (stage -1) [CORRECT]
C. Early postmenopause (stage +1a)
D. Late postmenopause (stage +2)
Correct Answer: B
Rationale: Correct because STRAW+10 defines late menopausal transition (stage -1) as the interval
from the first occurrence of ≥60 days of amenorrhea through 12 months after the final menstrual
period (FMP). This patient's last period was 7 months ago with FSH >35 mIU/mL and low estradiol,
placing her in stage -1. The ≥60-day amenorrhea criterion has been met, distinguishing this from
early transition (stage -2), which requires cycle length variation of ≥7 days.
Q2: A 48-year-old woman with a history of breast cancer treated with lumpectomy and radiation 5
years ago, currently on tamoxifen, presents with severe vasomotor symptoms affecting her quality of
life. She asks about hormone therapy. According to NAMS guidelines, what is the most appropriate
response?
A. Transdermal estradiol with micronized progesterone is safe in her case
B. Systemic estrogen-progestogen therapy is contraindicated due to her breast cancer history
[CORRECT]
C. Vaginal estrogen alone is contraindicated
D. Oral conjugated equine estrogen alone is acceptable given her tamoxifen use
Correct Answer: B
Rationale: Correct because a history of estrogen-dependent breast cancer is an absolute
contraindication to systemic menopausal hormone therapy per NAMS 2026 position statement.
While low-dose vaginal estrogen may be considered in select cases after discussion with oncology,
systemic estrogen-progestogen therapy is contraindicated. Tamoxifen does not mitigate the risk of
estrogen exposure in breast cancer survivors.
,Q3: Which of the following hormonal changes is the EARLIEST biomarker of declining ovarian
reserve during the menopause transition?
A. Rising FSH
B. Declining estradiol
C. Declining anti-Müllerian hormone (AMH) [CORRECT]
D. Rising LH
Correct Answer: C
Rationale: Correct because AMH is produced by granulosa cells of preantral and small antral
follicles and declines first in the reproductive aging process, often 5–10 years before FSH rises.
AMH is the earliest detectable hormonal marker of ovarian aging, making it the most sensitive
biomarker of declining ovarian reserve. FSH and LH rise later as negative feedback from estradiol
and inhibin B wanes.
Q4: A 60-year-old postmenopausal woman with osteoporosis (T-score -2.8 at the lumbar spine) and
moderate vasomotor symptoms cannot take MHT due to a history of VTE. Which non-hormonal
pharmacologic option has the strongest evidence for VMS reduction?
A. Black cohosh
B. Gabapentin
C. Paroxetine (7.5 mg) [CORRECT]
D. Acupuncture
Correct Answer: C
Rationale: Correct because paroxetine mesylate 7.5 mg (Brisdelle) is the only non-hormonal agent
FDA-approved for moderate-to-severe VMS and has the strongest evidence base among non-
hormonal options per NAMS guidelines. Gabapentin and venlafaxine have moderate evidence, while
black cohosh and acupuncture have inconsistent or limited evidence for VMS relief.
Q5: According to the timing hypothesis ("age and time" rule) for MHT initiation, what is the
maximum time from menopause onset for women under age 60 to initiate therapy and likely benefit?
A. 5 years
B. 8 years
C. 10 years [CORRECT]
D. 15 years
Correct Answer: C
Rationale: Correct because the timing hypothesis, supported by WHI reanalysis and NAMS 2026
guidelines, states that initiation of MHT within 10 years of menopause onset or before age 60 is
associated with more favorable benefit-risk ratios, particularly for cardiovascular outcomes. Beyond
this window, risks may outweigh benefits, especially for women initiating therapy after age 60.
,Q6: A 55-year-old woman with an intact uterus is started on MHT. She is prescribed transdermal
estradiol 0.05 mg/day. Which progestogen is most appropriate for endometrial protection according
to NAMS guidelines?
A. Medroxyprogesterone acetate (MPA) 10 mg daily
B. Norethindrone acetate 5 mg daily
C. Micronized progesterone 200 mg daily for 12 days per cycle [CORRECT]
D. Drospirenone 3 mg daily
Correct Answer: C
Rationale: Correct because NAMS 2026 guidelines recommend micronized progesterone or
dydrogesterone as the preferred progestogens for endometrial protection when combined with
estrogen in women with an intact uterus, due to a more favorable safety profile compared to
synthetic progestins like MPA. Micronized progesterone has lower breast cancer risk and does not
negate the cardiovascular benefits of transdermal estrogen.
Q7: What is the definition of premature ovarian insufficiency (POI)?
A. Menopause before age 45
B. Menopause before age 50
C. Menopause before age 40 [CORRECT]
D. Amenorrhea for 6 months before age 40
Correct Answer: C
Rationale: Correct because POI is defined as the loss of ovarian function before age 40,
characterized by amenorrhea (or oligomenorrhea) for ≥4 months with elevated FSH (>25 mIU/mL
on two occasions >4 weeks apart). Early menopause is defined as FMP before age 45, and late
menopause as FMP after age 54. POI requires confirmation with elevated gonadotropins.
Q8: A 58-year-old woman presents for her annual wellness visit. She has a DEXA T-score of -2.1 at
the femoral neck and -1.8 at the lumbar spine. She has no fractures but has a 10-year FRAX
probability of major osteoporotic fracture of 18%. According to NAMS and NOF guidelines, what is
the most appropriate initial pharmacologic management?
A. Calcium and vitamin D alone with repeat DEXA in 2 years
B. Oral bisphosphonate (alendronate or risedronate) [CORRECT]
C. Teriparatide as first-line therapy
D. Raloxifene
Correct Answer: B
Rationale: Correct because for a postmenopausal woman with osteopenia (T-score between -1.0 and
-2.5) and a 10-year FRAX major osteoporotic fracture risk ≥20% (or hip fracture risk ≥3%),
pharmacologic therapy is indicated. Oral bisphosphonates (alendronate, risedronate) are first -line per
NAMS and NOF guidelines. Teriparatide is reserved for high-risk patients or those who fail/cannot
tolerate bisphosphonates.
, Q9: Which ethnic/racial group of women has been shown to have lower estradiol levels during the
menopause transition compared to White, Black, and Hispanic women?
A. South Asian women
B. Chinese and Japanese women [CORRECT]
C. Native American women
D. Middle Eastern women
Correct Answer: B
Rationale: Correct because the Study of Women's Health Across the Nation (SWAN) and other
epidemiologic data have demonstrated that Chinese and Japanese women have lower estradiol levels
during the menopause transition compared to White, Black, and Hispanic women. This finding has
implications for symptom severity and MHT dosing in these populations.
Q10: A 50-year-old woman with an intact uterus is on oral conjugated equine estrogen (CEE) 0.625
mg daily for VMS. She develops new-onset leg swelling and is found to have a proximal DVT.
According to NAMS guidelines, which route of estrogen would have carried the LOWEST VTE
risk?
A. Oral estradiol
B. Oral CEE
C. Transdermal estradiol (patch or gel) [CORRECT]
D. Vaginal estradiol tablet
Correct Answer: C
Rationale: Correct because transdermal estrogen bypasses first-pass hepatic metabolism and does
not increase hepatic synthesis of clotting factors, resulting in a significantly lower risk of VTE
compared to oral estrogen. NAMS 2026 guidelines specifically recommend transdermal over oral
estrogen for women with VTE risk factors. Oral estrogen increases VTE risk 2- to 4-fold, while
transdermal estrogen shows no significant increase.
Q11: A 48-year-old woman with POI due to autoimmune oophoritis is currently on MHT. According
to NAMS guidelines, MHT should be continued until at least what age?
A. Age 50
B. Age 51 (mean age of natural menopause) [CORRECT]
C. Age 55
D. Age 60
Correct Answer: B
Rationale: Correct because NAMS guidelines recommend that women with POI should receive
MHT at least until the average age of natural menopause (approximately age 51) to protect bone,
cardiovascular, and neurological health, as their estrogen deficiency is premature and not age-
appropriate. MHT may be continued beyond age 51 based on individual risk-benefit assessment.
